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Abstract
This study examines the specificity and mechanism of action of a recently reported hepatitis C 
virus (HCV) non-structural protein 3 (NS3) helicase-protease inhibitor (HPI), and the interaction 
of HPI with the NS3 protease inhibitors telaprevir, boceprevir, danoprevir, and grazoprevir. HPI 
most effectively reduced cellular levels of subgenomic genotype 4a replicons, followed by 
genotypes 3a and 1b replicons. HPI had no effect on HCV genotype 2a or dengue virus replicon 
levels. Resistance evolved more slowly to HPI than telaprevir, and HPI inhibited telaprevir-
resistant replicons. Molecular modeling and analysis of the ability of HPI to inhibit peptide 
hydrolysis catalyzed by a variety of wildtype and mutant NS3 proteins suggested that HPI forms a 
bridge between the NS3 RNA-binding cleft and an allosteric site previously shown to bind other 
protease inhibitors. In most combinations, the antiviral effect of HPI was additive with telaprevir, 
boceprevir, minor synergy was observed with danoprevir and modest synergy was observed with 
grazoprevir.
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The hepatitis C virus (HCV) causes a common liver disease that if left untreated causes 
cirrhosis, hepatocellular carcinoma, and liver failure. HCV is a positive-sense RNA virus 
with a single long open reading frame encoding a ~3,000 amino acid long polyprotein, 
which is cleaved by host and viral proteases into structural (core, E1, and E2) and 
nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).1 HCV is a blood-
borne pathogen that replicates quickly after entering hepatocytes. Like most RNA viruses, 
HCV evolves rapidly, and these various hepatitis C viruses now comprise a diverse species 
with 7 genotypes (1–7), and several subtypes (e.g. 1a, 1b), whose sequences differ by 
typically 20–25%.2
Finding treatments for HCV has been challenging because the virus is challenging to study 
in the lab. HCV was not isolated until 1988,3 and HCV could not be cultivated in the 
laboratory until 2005.4 Until recently, HCV infection was treated with pegylated human 
interferon (pegIFN) and ribavirin, a regimen with limited efficacy and poor tolerability. 
PegIFN/ribavirin therapy eliminates detectable HCV in some patients, but side effects are 
worse than most early stages of hepatitis caused by HCV. Direct acting antivirals (DAAs) 
for HCV, in contrast, inhibit one of the HCV encoded proteins or enzymes needed for 
replication.5 DAA targets include the NS3 protein, which is an RNA helicase and a protease 
activated by NS4A, the NS5A RNA binding protein, and the NS5B RNA-dependent RNA 
polymerase. Most DAAs for HCV inhibit the NS3/NS4A protease, the NS5A protein, or the 
NS5B polymerase. The USA Food & Drug Administration recently approved the NS3-
NS4A protease inhibitors telaprevir, boceprevir, simeprevir, and paritaprevir, the NS5B 
inhibitors sofosbuvir and dasabuvir, and the NS5A inhibitors ledipasvir and ombitasvir. All-
oral DAA combination therapies combining these and other DAAs are effective even in the 
absence of PegIFN/ribavirin.6 However, costs of new DAA therapy still limit patient access, 
and new HCV drugs might still be valuable for HCV eradication.
We have been studying the helicase portion of NS3 as another possible drug target.7, 8 
Recently, we designed a series of NS3 helicase inhibitors from a component of the yellow 
dye primuline,9 one of which is also a NS3 protease inhibitor and an effective antiviral 
against HCV subgenomic replicons in cell culture.10 Similar concentrations of this new 
helicase-protease inhibitor (HPI, PubChem CID #50930749, Fig. 1) inhibit both the NS3 
helicase and protease functions in vitro, but not the ability of NS3 to cleave ATP, the fuel 
for helicase movement.10
The goals of this study were to better understand how HPI inhibits both the NS3 helicase 
and protease, and how HPI interacts with other protease inhibitors used to treat HCV 
infections. One possible explanation for the ability of HPI to inhibit both the NS3 protease 
and helicase would be if HPI non-specifically bound both NS3 domains. A lack of 
specificity might also explain the observed HPI antiviral affect if HPI also inhibits cellular 
proteins. We therefore first examined HPI specificity using the same Huh7.5 cell line stably 
transfected with HCV subgenomic replicons made from various HCV genotypes, and 
another cell line harboring subgenomic dengue virus replicons. We then attempted to select 
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for HCV resistant to HPI, and we examined the sensitivity of telaprevir-resistant HCV 
isolates to HPI.
Since the resulting data suggested that HPI specifically inhibits certain HCV genotypes in a 
manner different from peptidomimetic protease inhibitors, we then used molecular modeling 
to understand how HPI could inhibit both the NS3 helicase and protease. Prior studies with 
HPI analogues suggested that HPI binds in the NS3 RNA binding cleft,11 and in this pose, 
the fluorinated end of HPI protrudes from the helicase domain to contact a recently reported 
allosteric protease inhibitor-binding site.12 To test this binding model, we examined the 
ability of HPI to inhibit various recombinant NS3-NS4A complexes, proteins harboring 
amino acid substitutions in the putative HPI-binding cleft, and proteins with mutations in the 
region where peptidomimetic protease inhibitors bind.13 Results support the notion that HPI 
inhibits NS3-catalyzed peptide cleavage by binding an allosteric site, suggesting that HPI 
might be used to make HCV more sensitive to protease inhibitors that bind the NS3 protease 
active site. For example, HPI might lock NS3 in a conformation where NS3 would be more 
likely to bind other protease inhibitors. To test this idea, we examined subgenomic replicon 
sensitivity to various concentrations of HPI in combination with various concentrations of 
telaprevir, boceprevir, danoprevir14 or grazoprevir15 (Fig. 1). Synergy was observed 
between HPI and the macrocyclic inhibitors, but not the linear peptidomimetic inhibitors, 
supporting the notion that HPI might be a useful addition to antiviral therapies utilizing this 
new generation of HCV drugs.
Results
In an earlier report, Ndjomou et al. (2012)10 studied the effects of a series of benzothiazole 
compounds derived from the yellow dye primuline on the various functions of the HCV NS3 
protein. Many of these compounds, like NIH molecular probe ML283,16 specifically inhibit 
NS3-catalyzed RNA and DNA unwinding, but they do not potently inhibit the ability of NS3 
to cleave ATP and peptides. Primuline derivatives do not block helicase activity by 
inhibiting NS3-catalyzed ATP hydrolysis.11 Instead, they inhibit unwinding by causing the 
protein to release its nucleic acid substrate before unwinding is complete.17 Some primuline 
derivatives inhibit the ability of NS3 to unwind DNA & RNA and also the ability of NS3 to 
cleave peptides. Ndjomou et al. (2012) showed that one such dual-acting inhibitor, called 
“HPI” here (Fig. 1A), acts as a DAA by disrupting HCV replicase complexes in cells. 
Effects of HPI on NS3 protease were established using standard depsipeptide cleavage 
assays,18 and effects on the NS3 helicase were investigated using a molecular beacon-based 
helicase assay (MBHA).19 An MBHA monitors the ability of a helicase to displace a 
molecular beacon from a bound oligonucleotide upon ATP addition to cause an observable 
fluorescence decrease (Fig. 1B). HPI inhibits full-length NS3 in an MBHA (Fig. 1B), but the 
NS3 protease inhibitors telaprevir, boceprevir, danoprevir, and grazoprevir do not inhibit 
NS3 in an MBHA (Fig. 1C).
HPI specifically targets only some HCV genotypes
Previously, the antiviral potential of HPI was tested using a genotype 1b (con1 strain) 
subgenomic HCV replicon in which Renilla luciferase was fused to the neomycin 
Ndjomou et al. Page 3













transferase used for cell selection (HCVsg 1b(con1)-Rluc).10 To examine the effect of HPI 
on other HCV isolates, using the same Rluc reporter, a similar replicon was constructed 
using the genotype 2a JFH1 isolate.20, 21 HPI showed little activity against the HCVsg 
2a(JHF1) replicon (Fig. 2A). HPI did not affect the viability of cells containing either 
HCVsg 1b(con1) or HCVsg 2a(JFH1) at concentrations up to 100 μM, as was observed 
previously (data not shown).10 HPI was also tested in a Renilla lucifer-ase-tagged 
subgenomic dengue virus replicon,22 and no antiviral activity, and no effect on cell viability 
were observed (Fig. 2A). To test HPI on a wider variety of HCV genotypes, genotype 3a and 
4a hepatitis C virus replicons23 were also used to examine the antiviral activity of HPI. 
About half the concentration of HPI was needed to lower RNA levels of both the genotype 
3a and 4a replicons by 50% than was needed to lower the concentration of the genotype 1b 
replicon to the same extent (Fig. 2B). When colony-formation assays were used to compare 
the effect of HPI on HCV genotype 1b and 2a replicons, some antiviral activity was noted 
against genotype 2a (Fig. 2C).
To understand why HCV genotype 2a seems to be less sensitive to HPI than HCV genotypes 
1b, 3a, and 4a, we aligned the replicon sequences (Fig. S1, supporting information) and 
examined the location of amino acids present in genotype 2a but not the other HCV 
genotypes (Fig. 2D). Forty-one amino acids in genotype 2a NS3 are not conserved in the 
other three genotypes, and these are evenly distributed throughout each NS3 domain. While 
any of these substitutions could explain the resistance of genotype 2a to HPI, three unique 
genotype 2a residues are within 5 Å of the site in which HPI can bind NS3 in a computer-
generated model (see below). For example, Ala482 replaces a proline in the other genotypes. 
In the model, Pro482 appears to contact the fluorinated end of HPI. Two conserved 
threonines near HPI in the model are likewise not present in genotype 2a. Thr295 contacts 
the other end of HPI, and Thr435 contacts the center of HPI in the model (Fig. 2D).
HPI has higher barrier to resistance than the protease inhibitor telaprevir
To better understand how HPI might interact with NS3, we next attempted to select for HCV 
alleles encoding HPI resistance. Even after continued incubation of numerous replicon-
bearing cell lines with HPI, no noteworthy resistance to HPI could be detected. For example, 
when HCVsg 1b(con1) Huh7.5 cells were incubated with telaprevir for 3 weeks, the cells 
became resistant to telaprevir (Fig. 3A). In contrast, when the same cells were incubated 
twice as long with HPI, the sensitivity of the cell line to HPI did not change more than 2-
fold (Fig. 3B), and no mutations could be detected in the NS3 region. Cells that become 
resistant to telaprevir upon incubation retained sensitivity to HPI, and cells that were 
incubated with HPI retained sensitivity to telaprevir (data not shown).
We next examined if HPI was able to reduce cellular replicon levels if the replicons 
contained the telaprevir-resistant mutations R155K24 and V36A.25 In control experiments, 
4.2 times more telaprevir was required to inhibit replication of HCVsg 1b(con1) replicons 
harboring a R155K by 50% than was needed to inhibit wild type HCVsg 1b(con1), and 24 
times more telaprevir was needed to inhibit HCVsg 1b(con1) replicons harboring the R155K 
and V36A mutations (Fig. 4A). In contrast, HPI was equally active on HCVsg 1b(con1) 
replicons and telaprevir-resistant HCVsg 1b(con1) replicons (Fig. 4B).
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A molecular model predicting how HPI inhibits both the NS3 helicase and protease 
functions
To examine how HPI might modulate both the helicase and protease functions of NS3, we 
used molecular modeling to examine possible interactions of HPI with the known RNA-
binding cleft of the full-length NS3 protein using PDB file 1CU126 and UCSF Dock 6.27 
The modeling suggested that HPI could bind to full-length NS3 such that the fluorines 
decorating the terminal phenyl stack within 5 Å of His 57 in the catalytic triad of the NS3 
protease active site, while the other end of the molecule stacks in the helicase RNA binding 
cleft (Fig. 5A).
To test the validity of the modeled complex, we examined the ability of HPI to inhibit the 
protein crystallized in the 1CU1 complex, which is a “single-chain” recombinant protein 
where the activating region of NS4A is covalently tethered to the NS3 N-terminus (called 
here scNS4A-NS3).12, 26, 28, 29 In addition to the “wildtype” protein, we also examined the 
sensitivity of various HCV genotype 1a scNS4A-NS3 proteins harboring amino acid 
substitutions near the model-predicted HPI-binding site (S483A, M485A, V524A), and near 
the binding site of peptidomimetic protease inhibitors (F438A, Q526A, H528A).30, 31
Aydin et al. previously characterized the protease, helicase and ATPase functions of each of 
the mutant scNS4A-NS3 proteins used here.13 All of the proteins retain the ability to 
hydrolyze ATP, cleave peptides, and unwind duplex nucleic acids at rates comparable to the 
wildtype proteins.
We next sought to understand how HPI interacts with the NS3 helicase and protease active 
sites. Since both functions are difficult to monitor under steady-state conditions, we instead 
monitored HPI inhibitory effects under pseudo-first order conditions, where substrate 
concentrations were far lower than substrate Km’s observed in either the helicase assay32 or 
protease assay.18 Under these conditions, the concentration of HPI needed to reduce initial 
reaction rate by 50% would approximate a Ki if HPI acts as either a competitive or non-
competitive inhibitor. The same concentration of HPI was needed to inhibit the ability of all 
the proteins tested here to unwind DNA by 50% in MBHAs (data not shown). However, Ki 
values describing the ability of HPI to inhibit peptide cleavage catalyzed by the various 
recombinant NS3 proteins were notably different (Fig. 5B) assuming the enzyme variants all 
had Km values in the same range as those previously published for wildtype scNS4A-NS3 
(51±4 μM)33 or NS3 in the presence of pep4A (18±1 μM).33
The M485A substitution had the largest effect on the ability of HPI to inhibit NS3-catalyzed 
peptide cleavage. Specifically, replacement of Met485 with a smaller Ala, enhanced the 
ability of HPI to inhibit NS3-catalyzed peptide cleavage by about 5-fold (Fig. 5B). In our 
model, Met485 appears to block HPI access to the protease active site. HPI does not appear 
to bind like most peptidomimetic inhibitors because neither the Q526A nor H528A 
substitutions influenced the ability of HPI to inhibit the NS3 protease. Both Q526A and 
H528A were previously shown to affect the affinity of NS3 for a variety of different NS3 
peptidomimetic protease inhibitors.35
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Since NS4A and NS3 are not covalently tethered in the cell, we also examined the 
sensitivity of a recombinant full-length NS3 in the presence and absence of its NS4A 
cofactor to HPI. Interestingly, when NS3 was not fused to NS4A, considerably more HPI 
was needed to inhibit NS3-catalyzed peptide cleavage, both in the presence and absence of 
NS4A (Fig. 5B).
To understand if the putative HPI-binding site overlaps with other known protease inhibitor 
binding sites, the model was aligned with the crystal structures of various protease inhibitors 
bound to NS3 protease, such as 3M5L in which danoprevir is bound, and 3SUD in which 
grazoprevir is bound to the NS3 protease.31 The modeling suggested that NS3 could 
accommodate both HPI and grazoprevir (Fig. 5C), and as discussed below, these data 
support a model in which HPI facilitates grazoprevir binding by trapping NS3 in a compact 
conformation more likely to interact with the protease inhibitor.
Synergy between HPI and a macrocyclic NS3 protease inhibitor
To study the effect of HPI on HCV replicons in combination with other protease inhibitors, 
the effect of each agent alone on a stable subgenomic HCV replicon cell line was first 
examined (Table 1). Each agent was applied to Huh 7.5 cells with stable HCVsg 1b(con1)-
Rluc.36 After 72 hours, Rluc activity in cell extracts was measured.10 In control reactions, 
cell viability was monitored with various concentrations of each protease inhibitor, and the 
effect of each compound on RLuc activity present in cell extracts was assessed. The 
concentration of each compound needed to reduce cell viability by 50% (CC50) always 
greatly exceeded the concentration needed to reduce replicon content by 50% (EC50) (Table 
I).
The resulting EC50 values (Table 1) were used to design combination experiments where 
various concentrations of each of two compounds were applied in 7-point 2-fold dilution 
series with concentrations above the observed EC50 values and concentrations below the 
EC50 values obtained with each compound alone. Reactions were performed in triplicate, 
normalized, and compared to inhibition that would be expected from the Bliss independence 
model.37 Differences between observed and expected inhibition were plotted in three 
dimensions and the surfaces of the 3D plots were inspected for areas of synergy (positive, 
Fig. 6) and antagonism (negative, Fig. 6). In additional control experiments, we observed no 
reduction in cell viabilities in the presence of any concentration of any antiviral agent 
analyzed. None of the combinations affected the activity of Renilla luciferase present in 
crude cell lysates, and only HPI affected rates of NS3-catalyzed DNA or RNA unwinding 
(data not shown).
Prichard & Shipman define significant differences from Bliss additivity as those that yield 
volumes under the surfaces that are greater than 25 (μM2 %) in such a three-dimensional 
analysis, with minor but significant effects yielding volumes between 25 and 50, moderate 
effects yielding values between 50 and 100, and strong effects yielding values greater than 
100.37 Based on these definitions, no significant deviations from additive effects were 
observed when HPI was combined with telaprevir, or boceprevir (Fig. 6A, B). Minor, 
insignificant synergy was observed between HPI and danoprevir (Fig. 6C, where the volume 
under the plot is 17), but when HPI was combined with grazoprevir, strong synergy was 
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observed (Fig. 6D, where the volume under the plot is 101). The finding that HPI interacts 
with grazoprevir, but not with telaprevir and boceprevir supports the notion that HPI might 
alter the conformation of NS3 so that the enzyme is more sensitive to danoprevir and 
grazoprevir.
Discussion
This study shows that HPI (Fig. 1), a specific HCV antiviral (Fig. 2) that inhibits both the 
helicase and protease activity of the HCV NS3 protein, does not function like the 
peptidomimetic inhibitors in clinical use today. Instead of binding to the protease active site, 
HPI appears to exert its action by binding to an allosteric site between the helicase and 
protease domains (Fig. 5). HPI has a higher barrier to resistance (Fig. 3), is active against 
common protease inhibitor resistance alleles (Fig. 4), and can be used to enhance the 
efficacy of macrocyclic protease inhibitors (Fig. 6). This is also the first study to show that it 
is possible to target both the NS3 protease and helicase activities at the same time with 
different small molecules.
Hepatitis C virus NS3 is a multi-functional viral protein that plays at least two distinct roles 
in the virus life cycle, with the N-terminal domain cleaving viral and host proteins, and the 
C-terminal helicase unwinding duplex nucleic acids. This relationship provides a unique 
drug target because, other than NS3 encoded by HCV and related viruses, no other proteins 
are known to combine both protease and helicase activities in the same polypeptide. The two 
activities are tightly coupled with residues in the protease region promoting the helicase 
activity,38 residues in the helicase region enhancing the proteolytic activity,39 and the 
protease co-factor NS4A modulating RNA-stimulated helicase-catalyzed ATP hydrolysis.40
Numerous compounds that inhibit NS3-catalyzed peptide cleavage have been developed as 
antivirals,6 three of which (telaprevir, boceprevir, and simeprevir) have been already 
approved by the FDA. Telaprevir and boceprevir are linear peptidomimetics, but they 
preferentially inhibit certain HCV genotypes, and they must be administered with interferon 
and ribavirin because relatively fit drug-resistant HCV variants evolve rapidly. Newer 
protease inhibitors, represented here by danoprevir and grazoprevir, are macrocyclic 
peptidomimetics that are pan-genotypic, more potent, and more active against known 
resistant HCV variants (Fig. 1). Part of this enhanced activity derives from interactions with 
the helicase domain when the protein is in the compact conformation. P1-P3 macrocyclic 
protease inhibitors similar to danoprevir interact with residues Val524, Gln526, His528, and 
Met485.29 Compounds resembling grazoprevir with a P2-P4 macrocycle were designed to 
engage residues Gln526 and His528 on the helicase in addition to residues in the protease 
region.30 Interactions with the helicase domain also enhance the ability of macrocyclic 
compounds to inhibit the drug-resistant R155K and A156T variants.31, 41 A relevant 
observation here is that the mutation of residues suspected to interact with danoprevir or 
grazoprevir (i.e. Val524, Gln526, and His528) do not affect the ability of HPI to inhibit 
NS3-catalyzed peptide cleavage (Fig. 5), nor do telaprevir-resistant substitutions (R155K, 
V36A) influence the ability of HPI to inhibit subgenomic HCV replicons (Fig. 4). These 
data suggest that HPI does not bind in the same site as the peptidomimetic inhibitors.
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In a prior study, Ndjomou et al. reported that HPI10 inhibits the ability of NS3 to unwind 
DNA, unwind RNA, and cleave polypeptides, with a similar potency. However, much 
higher HPI concentrations are needed to inhibit NS3-catalyzed ATP hydrolysis.10 In a later 
study, Sweeney et al.11 used molecular modeling and site-directed mutagenesis to show that 
a compound similar to HPI (i.e. CID #50930756) binds NS3 helicase perpendicular to the 
known RNA binding cleft to trigger the movement of a so-called spring helix needed for 
RNA to reorient the ATP binding site and stimulate ATP hydrolysis. A similar binding site 
was observed here for HPI, although our new model of HPI bound to NS3 (Fig. 5) suggests 
that HPI bridges the helicase RNA-binding cleft to the cleft between the helicase and 
protease. In such a pose, the fluorinated part of HPI resides in the same site occupied by 
allosteric NS3 protease inhibitors reported by Astex pharmaceuticals, which also bind near 
Met485 in the NS3 helicase domain and Asp79 in the protease domain.12 Our observation 
that mutation of Met485 affects the inhibitory potential of HPI supports this binding model 
(Fig. 5). Nevertheless, molecular modeling of the binding of HPI to the NS3 protein is, by 
definition, speculative and does not alone explain the mode of HPI action. We are pursuing 
structural studies to better understand how HPI interacts with NS3 on a molecular level.
Another noteworthy observation is that scNS4A-NS3 fusion proteins are more sensitive to 
HPI inhibition than NS3 not fused to NS4A (Fig. 5B). These data could be explained by the 
fact that NS3 must adopt different conformations to cleave its diverse cellular substrates. To 
cleave the junction between NS3 and NS4A, NS3 must assume a compact conformation 
where the NS3 C-terminus resides in the protease active site. However, to cleave other 
substrates, NS3 must shift to a more extended conformation, in which the C-terminus of 
NS3 is no longer bound in the protease active site as a product inhibitor.26 An extended 
conformation is needed to cleave the other sites in the HCV polyprotein42 and cellular 
targets like the mitochondrial antiviral signaling protein MAVS43 and the Toll-like receptor 
3 adaptor protein TRIF.44
We propose that HPI is a better inhibitor of scNS4A-NS3 than NS3 because HPI must 
interact with the NS3 compact conformation to inhibit NS3-catalyzed peptide cleavage. All 
HCV scNS4A-NS3 proteins crystallized to date adopt a compact conformation,12, 26, 28, 29 
but native NS3 without covalently tethered NS4A has been shown to more readily assume 
an extended conformation.45 In our lab, all scNS4A-NS3 proteins migrate more rapidly on 
gel filtration columns than lower mass NS3 proteins, suggesting that NS3 is less compact 
than scNS4A-NS3. The substrate for assays used here to monitor NS3-catalyzed peptide 
cleavage is a short fluorescent depsipeptide, which could be cleaved when the protein is in 
either conformation. However, if HPI only inhibits the compact conformation, less HPI 
should be needed to inhibit recombinant purified NS3 constructs that primarily assume the 
compact conformation. Inhibiting NS3 by stabilizing a compact conformation is not new 
concept, and other compounds binding the helicase-protease interface, like the Astex 
inhibitors12 noted above, have also been proposed to lock the NS3-NS4A complex in a 
compact conformation. Unlike HPI, however, the Astex compounds have not been reported 
to influence the NS3 helicase activity. To date, only the compact conformation of HCV NS3 
has been captured in crystal structures, although the homologous complex from dengue virus 
(DENV) has been observed in an extended conformation with x-ray crystallography.46 
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Interestingly, HPI has no activity against dengue virus replicons (Fig. 2). Synergy between 
grazoprevir and HPI could therefore be explained if HPI stabilizes NS3 in a compact 
conformation so that NS3 will be more likely to interact with grazoprevir.
The final key observation reported here is that HCV appears to be less able to avoid the 
effects of HPI than other telaprevir (Fig. 2). Again, this is not a new observation for helicase 
inhibitors, as only one helicase inhibitor resistance allele has been reported in the literature, 
a T477A mutation resistant to a tropolone helicase inhibitor.47 The higher barrier of 
resistance to helicase inhibitors could make them useful additions to DAA therapies that 
lack a nucleotide NS5B inhibitor because circulating HCV strains already include many 
variants with alleles encoding resistance to DAAs targeting NS5A, the NS3 protease, and 
non-nucleotide NS5B inhibitors.48
Simultaneously targeting both the NS3 protease and helicase functions with small molecules 
is a novel therapeutic design approach that could be critical in future combination therapies. 
With its high barrier to resistance, novel mechanism of action, synergy with the latest 
macrocyclic protease inhibitors in development, HPI could be a valuable new agent in the 
DAA arsenal available to design more cost effective all-oral therapies to eradicate HCV.5
Methods
Materials
HPI (PubChem CID #50930749) was synthesized and purified as described.9 Telaprevir, 
danoprevir, and grazoprevir (MK-5172) were synthesized and purified as described.41 
Boceprevir was purchased from MedChem Express (Princeton, NY). All recombinant 
proteins were expressed in E. coli and purified as described for full-length NS3,49 scNS4A-
NS3 from genotype 1b (gt1b),50 and scNS4A-NS3 from genotype 1a (gt1a) and scNS4A-
NS3 mutants D79A, S483A, M485A, V524A, Q526A, and H528A.13
The sub genomic HCV genotype 1b(con1 strain) Renilla luciferase replicon (HCVsg 
1b(con1)-Rluc) and its stably transfected Huh7.5 cell line was the same as described 
before.9, 10 Plasmid S52/SG-Feo(AII), which encodes the HCVsg 3a(S52) replicon, and 
plasmid ED453/SG-FEO(VYG), which encodes the HCVsg 4a(ED43) replicon, were 
obtained from Dr. Charles Rice (Rockefeller University),23 Plasmid pYSGR-JFH-1,21 which 
encodes a J6/JFH1 infectious clone, was obtained from Brett Lindenbach (Yale University).
The HCVsg 2a(JFH1)-Rluc expression plasmid was constructed using a stepwise three-
fragment PCR-fusion strategy. First, the HCV 5′UTR was amplified from pYSGR-JFH-121 
with the forward primer RI-T7: 5′-GCC AGT GAA TTC TAA TAC GAC TCA CTA 
TAG-3′ (EcoRI restriction site underlined) and the reverse primer Core-R: 5′-GGG CGA 
CGG TTG GTG TTT CTT T-3′. The Rluc gene was amplified from HCVsg 1b(con1)-Rluc 
with the forward primer Core-RLuc-F: 5′-CAA CCG TCG CCC AAT GGC TTC CAA GGT 
GTA C-3′ and the reverse primer Rluc-FMDV2A-R: 5′-CGC AAG CTT AAG AAG GTC 
AAA ATT CAA CAG CTG CTG CTC GTT CTT CAG CAC-3′. The neomycin gene was 
amplified from pYSGR-JFH-1 with the forward primer FMDV2A-Neo-F: 5′-CTT CTT 
AAG CTT GCG GGA GAC GTC GAG TCC AAC CCT GGG CCC ATG ATT GAA CAA 
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GAT GGA TTG C-3′ and the reverse primer Neo-PmeI: 5′-GG GTT TAA ACT CAG AAG 
AAC TCG TCA AG-3′ (PmeI restriction site underlined). Second, the 5′UTR and Rluc 
fragments were fused using primers RI-T7 and RLuc-FMDV2A-R to make 5′UTR-Rluc 
fragment. Third, 5′UTR-Rluc fragment was fused to the neomycin fragment using primers 
RI-T7 and Neo-PmeI to make the final PCR fragment 5′UTR-RLuc-Neo that has the foot 
and mouth disease virus 2A (FMDV2A) peptide cleavage sequence between Renilla 
luciferase and neomycin genes. The resulting PCR product (5′UTR-Rluc-Neo) was then 
digested with EcoRI and PmeI and cloned into EcoRI/PmeI digested pYSGR-JFH-1 
backbone to yield pRluc-HCVsg 2a(JFH1), the sequence of which was confirmed by 
sequencing.
Site-directed mutagenesis was performed on the HCVsg 1b(con1) plasmid using the 
QuikChange II kit (Agilent Technologies, La Jolla, CA). The R155K mutation was 
introduced in NS3 using the forward primer 5′-GCA CGC TGT GGG CAT CTT TAA GGC 
TGC CGT G-3′ and the reverse primer 5′-CAC GGC AGC CTT AAA GAT GCC CAC 
AGC GTG C-3′. The NS3 protease double mutant R155K/V36A was constructed by 
introducing the V36A mutation in the R155K plasmid backbone with primers 5′-GGG AGG 
TCC AAG CGG TCT CCA CCG C-3′ and 5′-GCG GTG GAG ACC GCT TGG ACC TC 
CC-3′. Mutations were confirmed by DNA sequencing.
HCV subgenomic replicon assays
All subgenomic replicon containing Huh-7.5 cells were isolated and maintained as 
previously described,10 To assess the ability of each compound to inhibit HCV replication, 
Huh7.5 cells harboring HCV Rluc subgenomic replicons were seeded at 10 × 103 cells per 
well in 96-well plates and incubated 4–5 hours to allow the cells to attach to the plate. Two-
fold serial compound dilutions were made in dimethyl sulfoxide (DMSO), and diluted into 
media, such that the DMSO final concentration was 0.5% after adding dilutions to cells. 
Compounds and cells were incubated at 37 °C in 5% CO2. After 3 days, Renilla luciferase 
was measured using Promega’s Renilla luciferase assay kit. Quantitative reverse 
transcriptase PCR using Taqman probes specific to conserved sequences in the HCV 5′UTR 
was used to measure relative RNA levels as previously described.10 PCR data were 
normalized to RNA levels observed in cells incubated with DMSO only.
Dengue virus subgenomic replicon assay
Baby hamster kidney (BHK-21) cells were stably transfected with the replicon described by 
Stahla-Beek et al.22 using a replicon plasmid obtained from Brian J. Geiss (Colorado State). 
Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, LifeTech) 
containing 4.5 g/l D-glucose, L-glutamine, and 110mg/L sodium pyruvate and supplemented 
with 10% FBS, 100 U/mL each of penicillin and streptomycin and 3 μg/mL puromycin to 
maintain replicons stability, seeded in clear 96-well culture plates (Corning #3599) without 
puromycin at a concentration of 1,000 cells per well. Cells were allowed to adhere, and HPI 
dissolved in DMSO and diluted in DMEM was added to cells such that the final volume in 
the well was 100 μl, and the final DMSO concentration was 1%. The effect of compounds 
on replication was assessed by measuring Renilla luciferase reporter gene activity as 
described above.
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To assess compound effects on Huh-7.5 or BHK DENV-Rluc cell viability, cells were plated 
and treated as above for compound inhibitory activity and the effect of compound on cell 
viability was tested using the CellTiter-Glo luminescent cell viability kit (Promega).
Colony formation assays
Huh-7.5 HCVsg 1b(con1)-Rluc replicon cells were plated at 2 × 105 cells per well in 6-well 
plates in complete DMEM in the presence of 350 μg/ml G418. Cells were treated with HPI 
(25 μM and 100 μM) or telaprevir (1 μM and 10 μM) or the DMSO control and incubated 
for 3 days after which a fresh dose of compounds or DMSO was added to the cells. Media 
containing fresh aliquots of compounds (HPI or telaprevir) or DMSO was added every 3 
days for two weeks. The cells were washed with PBS, fixed with 4% PFA and stained with 
0.5% crystal violet solution for 30 min at room temperature, then washed extensively with 
ddH2O until no colored crystal solution was observed.
Resistance selection
Huh7.5 cells bearing HCVsg 1b(con1)-Rluc replicons were exposed to various 
concentrations of HPI, telaprevir (positive control) or DMSO alone (negative control) 
corresponding to 0.25×, 0.5×, 1×, 2.5×, 5×, and 10× the IC50 value for the compound and 
incubated in the presence of 350 μg/ml G418 selection. Media containing fresh aliquots of 
HPI or telaprevir was replenished every 3 to 4 days and upon cell splitting. After 3 or 6 
weeks of continued selection, the susceptibility of evolved cells lines to HPI and telaprevir 
was tested by measuring Renilla luciferase remaining after exposure to various amounts of 
each compound.
Molecular Modeling
HPI was docked into PDB file 1CU126 that was stripped of its ligands. Water molecules and 
counterions were removed from each PDB file, and incomplete side chains were filled using 
UCSF Chimera 1.6.2.34 Using UCSF Chimera’s Dock Prep module, histidine protonation 
states were calculated, and incomplete side chains were automatically filled. A three-
dimensional conformation of HPI was generated using Open Babel GUI, was saved as a 
PDB file, and positioned using a rigid body orienting code in UCSF DOCK 6.5.27 The 
ligand-binding site of the protein was constrained to be the largest cluster of spheres 
surrounding the molecular surface of the protein as generated by UCSF DOCKS’s sphgen 
module.
Protease assays
HCV NS3 depsipeptide cleavage assays18 were performed with the 5-FAM/QXL™520 
substrate (Anaspec), which is based on the NS4A/NS4B cleavage site. Each 20 μl assay 
contained 50 mM Tris–HCl pH 7.0, 50% glycerol, 2% CHAPS, 30 mM DTT, 5% DMSO, 
and 0.5 μM 5-FAM/QXL™520 substrate. When NS3 lacking a covalently tethered NS4A 
was used, reactions were supplemented with 6 μM pep4AK (Anaspec). Reactions were first 
performed with various concentrations of each NS3 protein to determine its specific activity. 
A unit of enzyme was defined as the amount needed to cleave 0.05 μM of substrate/min. To 
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determine the inhibitory potential of HPI with each enzyme, reactions were performed with 
1 unit of each enzyme with various concentrations of HPI. Reactions containing HPI were 
performed in the presence of a 16-pt two-fold dilution series of HPI starting at 100 μM. 
Assays were performed in duplicate, and rates normalized to reactions performed in the 
absence of HPI. Initial rates of substrate cleavage were then plotted verses HPI 
concentration and fitted to a concentration response equation to calculate the concentration 
of HPI needed to reduce initial rates by 50% using GraphPad Prism (v.6).
Helicase assays
Molecular-beacon based helicases assays32 were performed and data analyzed as described 
by Hanson et al.19 Reactions were performed in the presence of 50 nM NS3, 12.5 nM 
substrate, and 12 different HPI concentrations ranging from 1 to 100 μM. Unwinding rates 
were calculated from the slopes immediately following ATP addition.
Combination studies
Two-fold serial dilutions, starting at ~4 times the EC50 values obtained in concentration-
response assays with each compound alone, were prepared in 96-well plates. 50 μl of each 
dilution of the first compound to be tested (at twice the final compound concentration) was 
added horizontally and 50 μl of each dilution of the second compound was added vertically 
to make a 1× final concentration of each compound. After 3 days at 37 °C, luciferase 
activity was measured. At least four separate experiments (in triplicate) were performed for 
each combination.
Data analysis
Half-maximal inhibitory concentrations were calculated from concentration response curves 
using nonlinear regression to fit data to a log(inhibitor) vs. normalized response equation 
with variable slope. The effects of drug-drug combinations were evaluated using the 
MacSynergy II (http://www.uab.edu/medicine/peds/macsynergy).37, 51 MacSynergy II uses 
the Bliss independence model to estimate synergy and/or antagonism. Additive inhibition is 
calculated in MacSynergy using the equation Z = X + Y (1−X), where X and Y correspond 
to the inhibitory effects of compound 1 and 2 respectively, and Z is the effect produced 
when the two compounds are combined. Resulting values are then subtracted from the 
normalized inhibition observed at each drug combination to estimate synergy (positive 
values) or antagonism (negative values). Synergy/antagonism values calculated using the 
MacSynergy II Excel spreadsheet at the 95% confidence levels were plotted in three 
dimensions using DeltaGraph 6 (Redrock Software).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Effect of HPI and other protease inhibitors on the ability of NS3 to unwind DNA. (A) Direct 
acting antivirals used in this study. (B) Ability of HPI to inhibit molecular beacon-based 
helicase assays (MBHAs). In MBHAs, NS3 separates a molecular beacon from a 
complementary strand so that fluorescence decreases with time. (C) Activity remaining, 
calculated from normalized initial velocities, in the presence of various NS3 protease 
inhibitors (data for boceprevir and danoprevir are omitted for clarity. Neither inhibit the 
reaction). Data were fitted to a normalized concentration-response equation using Graphpad 
Prism v.6. The IC50 value for HPI was 6±2 μM.
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HPI specificity. (A) The ability of HPI to reduce cellular content of Renilla luciferase tagged 
subgenomic replicons made from HCV genotype 1b (HCVsg 1b(con1), circles), HCV 
genotype 2a (HCVsg 2a(JFH1), squares) and dengue virus strain 2 (DENVsg 2, triangles) 
(B) Effect of various HPI concentrations on relative levels of subgenomic replicon RNA, as 
measured by quantitative reverse-transcriptase PCR, with data normalized to RNA levels 
seen in cells treated with DMSO only. (C) Colony formation units (CFU) of Huh7.5 cell 
cultures harboring the HCVsg 1b(con1) or the HCVsg 2a(JFH1) replicon. Cells were 
initially plated at 2 × 105 cells/dish, and G418-resistant colonies were stained with crystal 
violet after 3 weeks of antibiotic selection. Note CFUs for the HCVsg 2a(JFH1) replicon 
were about 10 times higher than CFUs observed with HCVsg 1b(con1) in the absence of 
HPI or telaprevir. (D) Unique residues in genotype 2a(JFH1) are highlighted on the 
scNS4A-NS3 structure in which HPI is docked. Residues pesent in 2a(JFH1) NS3 but not 
genotypes 1a(H77), 1b(con1), 3a(S52), or 4a(ED42) are highlighted as spheres with unique 
amino acids within 5 Å of HPI noted with arrows. Sequence alignments are shown in Figure 
S1 (Supporting Information).
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Evolution of HCV resistant to telaprevir and HPI. (A) Sensitivity of the HCVsg 1b(con1)-
Rluc replicon to telaprevir after incubation with DMSO (circles) or telaprevir (squares) for 3 
weeks. (B) Sensitivity of the HCVsg 1b(con1)-Rluc replicon to HPI after incubation with 
DMSO (circles) or HPI for 3 weeks (trangles) or 6 weeks (squares). After 3 or 6 weeks of 
selection, the susceptibility of evolved cells lines to each compound was determined by 
measuring Renilla luciferase activity remaining after exposure to various amounts of each 
telaprevir or HPI for 3 days.
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Sensitivity of HCVsg 1b(con1)-Rluc replicons carrying telaprevir-resistance mutations. (A) 
Normalized Renilla luciferase remaining after exposure of HCVsg 1b(con1) (circles), 
HCVsg 1b(con1) carrying the NS3 R155K substitution (squares), or HCVsg 1b(con1) 
carrying both a R155K and V36A substitutions (triangles) to various amounts of telaprevir 
for 3 days. (B) Normalized Renilla luciferase remaining after exposure of HCVsg 1b(con1) 
(circles), HCVsg 1b(con1) carrying the NS3 R155K substitution (squares), or HCVsg 
1b(con1) carrying both a R155K and V36A substitutions (triangles) to various amounts of 
HPI for 3 days.
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The possible HPI-binding site on NS3. (A) Position of HPI when docked in the full-length 
HCV NS3 structure (PDB 1CU1). The putative HPI binding site is highlighted as a surface 
on a wireframe NS3 model with the helicase red and protease blue. Residues targeted for 
site-directed mutagenesis are shown as sticks. Natural ligand-binding sites are labeled in 
grey. (B) Inhibitory constant (Ki) describing the ability of HPI to inhibit NS3-catalyzed 
peptide hydrolysis. Wildtype scNS4A-NS3 is grey, amino acid substitutions in the putative 
HPI-binding site are red, and amino acid substitutions in the cleft that binds protease 
substrates are blue. Full-length NS3 constructs lacking the covalent tether to NS4A are 
white. (C) Position of docked HPI in realtion to the various NS3 active sites, ligand binding 
clefts, and the peptidomimetic protease inhibitor-binding site. Position of grazoprevir was 
determined by aligning the grazoprevir costructure with the NS3 protease (PDB file 
3SUD)31 with the structure of full-length NS3 (PDB file 1CU1).26 The protease domain is 
blue, NS4A is green, and the helicase is red. Models were rendered using UCSF Chimera 
1.8.34
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Figure 6. Interactions between HPI and other protease inhibitors
Points on the z-axes represent the difference in replicon inhibition observed from the 
inhibition that would be expected if the two agents produced additive effects in the Bliss 
independence model when compounds inhibited the HCVsg 1b(con1)-Rluc replicon with the 
IC50 values listed in Table 1. In each 3D plot, combinations yielding synergy are 
progressively lighter grey. Data were analyzed using MacSynergy II.37
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Table 1
Ability of various DAAs to inhibit the genotype 1b subgenomic replicons and Huh7.5 cell viability
Compound EC50 (μM)a CC50 (μM)b
HPI 15 ± 4 >100
Telaprevir 0.81 ± 0.4 45 ± 4
Boceprevir 0.64 ± 0.1 > 100
Danoprevir 0.002 ± 0.0005 100
Grazoprevir 0.00076 ± 0.00013 54 ± 5
a
EC50 values represent the concentration of each compound needed to reduce cellular HCVsg 1b(con1)-Rluc replicon content by 50% relative to 
cells treated with DMSO alone.
b
CC50 values are concentrations needed to reduce cell viability by 50%.
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